Why Beta-Blockers Are Not Recommended in HFpEF
Beta-blockers are not routinely recommended in HFpEF because randomized controlled trials have consistently failed to demonstrate mortality or morbidity benefit, and emerging evidence suggests they may actually worsen outcomes—particularly heart failure hospitalizations—by limiting the chronotropic response needed to maintain cardiac output during exercise in patients who already have impaired diastolic function. 1
The Pathophysiological Problem
HFpEF is fundamentally characterized by:
- Reduced left ventricular compliance and elevated filling pressures that limit stroke volume augmentation during exercise 2
- Dependence on heart rate increases to maintain cardiac output during physical activity, since stroke volume cannot adequately rise 2
- Chronotropic incompetence that is already present in many HFpEF patients, contributing significantly to their exercise intolerance 3
Beta-blockers directly antagonize the compensatory mechanism these patients rely on by blunting heart rate response, thereby worsening their already limited exercise capacity and exacerbating symptoms. 1, 2
The Evidence Base
Guideline Position
The 2023 ACC Expert Consensus explicitly states that beta-blockers showed no benefit in HFpEF trials and should only be used when specific alternative indications exist (prior myocardial infarction within 3 years, angina, or atrial fibrillation), with careful monitoring of exercise tolerance due to chronotropic incompetence risk. 1
Clinical Trial Evidence Shows Harm
Recent high-quality observational data demonstrates:
- In the PINNACLE Registry (435,897 patients), beta-blocker use was associated with higher risk of HF hospitalization as ejection fraction increased, with particular harm when EF exceeded 60% 4
- The interaction between EF and beta-blocker outcomes was significant (p<0.001), showing benefit in HFmrEF but potential risk in HFpEF 4
- In the PurSuit-HFpEF Registry, patients without atrial fibrillation or ischemic heart disease who received beta-blockers had significantly higher all-cause mortality (HR 1.448, p=0.046) and cardiac death (HR 2.380, p=0.001) 5
Neutral Outcomes at Best
- The SwedeHF Registry (14,434 patients) found no association between beta-blocker use and HF hospitalization (HR 0.95, p=0.31) or cardiovascular death (HR 0.94, p=0.19) in propensity-matched analysis 6
- Meta-analysis of 5 RCTs (538 patients) showed beta-blockers did not improve NYHA class, exercise capacity, or BNP levels compared to control 3
When Beta-Blockers May Be Appropriate
Beta-blockers should be reserved for HFpEF patients with compelling alternative indications: 1
- Recent myocardial infarction (within 3 years post-MI) 1
- Angina pectoris requiring rate control 1
- Atrial fibrillation requiring ventricular rate control 1, 7
In these specific subgroups, meta-regression analysis suggests beta-blockers may reduce NYHA class and BNP levels, likely by treating the underlying comorbidity rather than HFpEF itself. 3
Critical Caveat: Monitor Exercise Tolerance
When beta-blockers must be used for alternative indications, clinicians must actively monitor for worsening chronotropic incompetence and exercise intolerance, as this represents a predictable adverse effect in the HFpEF population. 1
The Contrast With Proven HFpEF Therapies
Unlike beta-blockers, SGLT2 inhibitors (dapagliflozin, empagliflozin) have demonstrated clear benefit with hazard ratios of 0.82 and 0.79 for cardiovascular death or HF hospitalization in DELIVER and EMPEROR-PRESERVED trials respectively, establishing them as foundational disease-modifying therapy. 1, 8, 9
The failure of neurohormonal blockade strategies (beta-blockers, ACE inhibitors, ARBs) in HFpEF validates that this syndrome requires metabolic and anti-inflammatory interventions rather than traditional heart failure pharmacology developed for reduced ejection fraction. 8, 9